UCB to acquire Candid Therapeutics in $2.2Bn deal focused on autoimmune T-Cell engagers
BRUSSELS: UCB, a global biopharmaceutical company, announced Tuesday it has signed a definitive agreement to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company developing novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases. Under the terms of the agreement, UCB will pay $2 billion upfront, with an additional $200 million in potential future milestone…